Business Wire

Morinaga Milk Reveals Major Breakthroughs in a ‘Bifidobacteria Training’ Program With Professional Footballer Yuto Nagatomo

31.8.2021 20:52:00 EEST | Business Wire | Press release

Share

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a pioneer in bifidobacteria and gut microbiota research, reveals that its collaborative ‘Bifidobacteria Training’ project (launched in June 2020) helped professional athlete Yuto Nagatomo improve his gut microbiota. Nagatomo stayed on the program for a full year, and has been outspoken about the changes in his gut microbiota that not only improved his digestive system, but also his physical condition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005058/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

In recent crosstalk, footballer Yuto Nagatomo speaks passionately about his full year on the ‘Bifidobacteria Training’ program. “My condition improved because I stayed with it.” “Bifidobacteria ‘saved me’”, he shared. (Graphic: Business Wire)

About the ‘Bifidobacteria Training’ program

The program encourages participants to incorporate bifidobacteria into their existing knowledge, diet, and physical and mental health regimens with the aim of improving the environment of the large intestine through input from inside and outside the body.

The ‘Bifidobacteria Training’ program website offers a wealth of information not available elsewhere, including varied content on knowledge, diet, exercise, and mental health, and a profile of Yuto Nagatomo’s gut microbiota shaped by his consistent intake of bifidobacteria since 2020.

1. Overview of Report on ‘Bifidobacteria Training’ CROSS-TALK 2020-2021

Footballer Yuto Nagatomo started taking bifidobacteria in July 2020, during the offseason. He later signed with a French (Ligue 1) team, and his condition suffered as he attempted to adapt to an unfamiliar living environment. However, his digestive system steadily regained its balance thanks to his persistence with the ‘Bifidobacteria Training’ program. Our analysis of his gut microbiota revealed inconsistency immediately after his move to France, followed by certain changes that suggested a strong connection between his enteric bacteria and his physical condition.

Nagatomo recognized the changes as they were occurring. “My condition improved because I stayed with the ‘Bifidobacteria Training’ program every day,” he said. “Even on days I couldn’t sleep, both my digestive system and my physical condition were stable.” He also noted that his recovery speed had improved, and identified the source without uncertainty. “[Bifidobacteria] saved me.” His condition and performance on the field continuously improved. “I’m so much more confident now that I have the final piece of the puzzle in my goal to represent Japan in the 2022 World Cup.”

He reflected on his full year on the ‘Bifidobacteria Training’ program, noting that staying with it was important, yet not all that burdensome. “[Staying with the program] was everything for my gut microbiota,” he said in a nod to a Japanese adage about the value of persistence in sport. “It helped me so much. I’m grateful for the support.”

2. Changes in Yuto Nagatomo’s gut microbiota on the ‘Bifidobacteria Training’ program

Dr. Toshitaka Odamaki, Manager of the Microbiota Research Department at the Next Generation Science Institute of Morinaga Milk, analyzed Nagatomo’s gut microbiota over the roughly seven months in which he took bifidobacteria. “The balance of enteric bacteria shifted substantially after [Nagatomo] moved from Japan to France, but his intake of bifidobacteria and balanced meals created a new balance that stabilized in December,” Dr. Odamaki said, also confirming the disappearance of the harmful bacteria may be associated with the cause of Nagatomo’s illnesses. “The analysis showed increases in good bacteria such as bifidobacteria and butyrate-producing bacteria following his persistence with the ‘Bifidobacteria Training’ program.” Dr. Odamaki also noted that Nagatomo had a growing population of bacteria that is linked to the performance of professional athletes.” The changes in gut microbiota could be a factor behind Nagatomo’s sense that his condition improved.”

“This is the first experience to track the detailed changes in an individual’s gut microbial composition,” Dr. Odamaki said. “Our analysis illustrated a strong connection between tangible feelings and enteric bacteria, which are normally hidden from us, a significant finding among Morinaga Milk’s research.”

About professional footballer Yuto Nagatomo

Born in Ehime Prefecture, Japan in 1986. Made his official J. League debut with FC Tokyo in 2008. Invited to play on the Japanese national team for the first time in May 2008, and appeared in the Beijing Olympics in August of that year. Played every minute of Japan’s four games in the 2010 World Cup in South Africa, signed with Cesena of Serie A (Italy) in July of that year. Signed with the vaunted Inter Milan in January 2011. Played every minute of Japan’s games in the 2014 World Cup in Brazil. Joined Galatasaray S.K. of the TFF 1. Lig (Turkey) on loan in 2018. Advanced to the finals for the first time at the 2018 World Cup in Russia. Joined Galatasaray S.K. on a permanent deal in 2019, and won two consecutive Süper Lig titles and two Turkish Cup trophies. Signed with Olympique de Marseilles of Ligue 1 (France) on August 31, 2020. Developed original exercise methods incorporating elements of stretching, yoga, and core training, worked with a personal chef and physician to develop a fat-adaptation diet, and more. With a style of examining his body from the inside and outside, he continues to maintain a high level of athletic performance, and has declared his goal to represent Japan in the 2022 World Cup.

About Morinaga Milk’s initiatives with Yuto Nagatomo

Morinaga Milk sensed Yuto Nagatomo’s dedication to constant improvement as a professional athlete, evident in his commitment to physical fitness, diet, and other facets of health within his control. We heard of his concern about his digestive system suffering during extended stays outside Japan despite unflagging self-control, and wanted to apply our findings from many years of research to try to improve his intestinal environment and help him continue to evolve as an athlete from the inside out.

Additionally, “nurturing the next generation” is one of the themes of ESG-focused management, a basic policy from our Medium-Term Business Plan. We aim to teach people the importance of food for maintaining healthy bodies and minds, while also helping them grow as people with positive attributes like agency, autonomy, and motivation to take on challenges, all in an effort to nurture the next generation in order to create a sustainable society.

These goals resonate with Nagatomo, who for his part has established the Yuto Nagatomo Football Academy (YNFA), founded Cuore Inc. with the aim of using his influence as an athlete to solve health problems around the world, and devoted energy to activities in support of single-parent families.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Morinaga Milk Industry Co., Ltd.
Investor& Public Relations Department
Ryo Mikami/Mitsunori Watanabe
International Division
Junichi Minami /Chyn Boon Wong
E-mail: interntl-pr@morinagamilk.co.jp
Morinaga Milk website: https://www.morinagamilk.co.jp/english/
Morinaga Probiotics Center website: https://morinagamilk-ingredients.com/
Morinaga Probiotics Center LinkedIn: https://www.linkedin.com/company/morinaga-probiotics-center

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye